| Amarnauth Singh, MD | |
|
13460 N 94th Drive, Ste J-1, Peoria, AZ 85381-4246 | |
| (623) 876-8816 | |
| (623) 298-0168 |
| Full Name | Amarnauth Singh |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 49 Years |
| Location | 13460 N 94th Drive, Peoria, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639170764 | NPI | - | NPPES |
| 789547 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 31199 (Arizona) | Secondary |
| 207RC0001X | Internal Medicine - Clinical Cardiac Electrophysiology | 31199 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yuma Regional Medical Center | Yuma, AZ | Hospital |
| Arrowhead Hospital | Glendale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yuma Regional Medical Center | 2062314826 | 288 |
| Vhs Outpatient Clinics Inc | 4486566726 | 157 |
| Joseph A Caplan Md Pc | 5890687842 | 32 |
| Phoenix Heart Pllc | 7113906421 | 15 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
| Entity Name | Vhs Outpatient Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912979964 PECOS PAC ID: 4486566726 Enrollment ID: O20031104000523 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
| Entity Name | Yuma Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194706655 PECOS PAC ID: 2062314826 Enrollment ID: O20040122000526 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
| Entity Name | Joseph A Caplan Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649389156 PECOS PAC ID: 5890687842 Enrollment ID: O20040325001456 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
| Entity Name | Phoenix Heart Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679608095 PECOS PAC ID: 7113906421 Enrollment ID: O20040719001045 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
| Entity Name | Hospital Development Of West Phoenix Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013100692 PECOS PAC ID: 4981515764 Enrollment ID: O20080118000329 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amarnauth Singh, MD 13460 N 94th Drive, Ste J-1, Peoria, AZ 85381-4246 Ph: (623) 876-8816 | Amarnauth Singh, MD 13460 N 94th Drive, Ste J-1, Peoria, AZ 85381-4246 Ph: (623) 876-8816 |
News Archive
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
APWU Health Plan announces new rates and benefits for 2011. APWU Health Plan continues to offer comprehensive health care to America's Workforce at a competitive premium. The average rate increase for the FEHB Program in 2011 is 7.2 percent. For the tenth straight year, the APWU Health Plan's rate increase was below the FEHB average.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).
Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has filed its annual report for the fiscal year ended December 31, 2009 on Form 20-F with the U.S. Securities and Exchange Commission on June 30, 2010.
› Verified 3 days ago
Moustafa Banna, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 13460 N 94th Dr Ste J1, Peoria, AZ 85381 Phone: 623-876-8816 Fax: 623-298-0168 | |
Dr. Akshay Vijay Shah, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave, Suite 122, Peoria, AZ 85381 Phone: 623-773-1161 Fax: 623-773-1181 | |
Brent Smoots, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15525 N 83rd Ave Ste 104, Peoria, AZ 85382 Phone: 877-809-5092 | |
Wilbur Knowlton Freeman Iii, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 13460 N 94th Drive Ste. J-1, Peoria, AZ 85381 Phone: 623-876-8816 Fax: 623-298-0168 | |
Gilbert Ortega, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 13965 N 75th Ave, Peoria, AZ 85381 Phone: 602-734-0252 | |
Manoj Rawal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 13460 N 94th Drive, Ste J-1, Peoria, AZ 85381 Phone: 623-876-8816 Fax: 623-298-0168 | |
Dr. Robert R Orr, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9171 W Thunderbird Rd, Suite 101, Peoria, AZ 85381 Phone: 623-815-7800 Fax: 623-815-7900 |